Avecho restarts recruitment for final stage of pivotal Phase III insomnia trial
Avecho Biotechnology (ASX: AVE) has recommenced recruitment for the final stage of its pivotal Phase III clinical trial evaluating its TPM®-enhanced cannabidiol (CBD) soft-gel capsule for the treatment of insomnia.
The restart follows a positive interim analysis announced in June 2026, which the company says materially de-risked the study. Approximately 320 additional participants will be enrolled in the second cohort to bring the trial to its originally planned size of 519 participants completing the study.
Once additional sites are operational, recruitment of the remaining participants is expected to be completed within approximately 12 months. A successful outcome would mark the final clinical step before a potential submission to the Therapeutic Goods Administration (TGA) for pharmaceutical registration.
When big ASX news breaks, our subscribers know first
What the interim analysis result means for the trial
The interim analysis was described by Chief Executive Officer Dr Paul Gavin as the single biggest risk to the study. Following its review of the unblinded interim data, the independent Data Monitoring Board (DMB) unanimously recommended that the trial continue to its originally planned size of 519 participants, with no increase to the sample size.
Why does holding the sample size steady matter? A trial’s size is set from assumptions about how well a treatment is expected to work and how much patients naturally vary. A weaker or more variable interim result would typically call for more participants. By recommending the study continue at its planned size rather than expanding it, the DMB signalled that the trial is appropriately sized and tracking in line with its original design.
Importantly, this is a structural signal, not an efficacy readout. Avecho remains blinded to all treatment allocations and efficacy data, which will not be available until the study is completed and the final data analysed.
The interim analysis outcome has since been unpacked in detail, with the DMB recommendation to hold the original 519-participant sample size interpreted as consistent with treatment effect assumptions tracking at or better than the trial’s original design expectations.
The interim analysis was conducted using data from 244 participants. The DMB, comprising independent experts in sleep medicine, clinical safety and biostatistics, is the only body with access to the trial’s unblinded data. It determined that the study had satisfied the pre-specified criteria established in the trial protocol.
Safety data reviewed as part of the interim analysis identified no serious adverse events among the 244 participants assessed across the trial’s three treatment groups.
Dr Paul Gavin, Chief Executive Officer
“The interim analysis was the most significant milestone in this program and, in our view, the single biggest risk to the study. With that risk now behind us and the trial materially de-risked, we are recommencing dosing of the final cohort of patients, confident we are on the path to a successful completion of this pivotal Phase III study.”
How the Phase III study is designed
The trial is structured to provide robust clinical evidence for regulators. Its core design features include:
-
Multi-centre, randomised, double-blind and placebo-controlled
-
Three treatment arms: nightly 75mg CBD, 150mg CBD, or placebo
-
An eight-week treatment period
-
Validated questionnaires and daily sleep diaries measuring insomnia severity and sleep quality
-
Study Identifier: NCT05840822
The study is described as the largest of its kind testing cannabidiol, taking place at multiple sites across Australia. Aided by advice from international sleep and regulatory experts, the trial has been designed to meet the requirements of the TGA, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The insomnia market opportunity
Insomnia is a sleep disorder defined by dissatisfaction with sleep quantity or quality, associated with difficulty initiating or maintaining sleep and the inability to return to sleep on awakening. Chronic insomnia, the most prevalent manifestation, is characterised by symptoms occurring at least three nights per week for at least three months.
The condition carries a substantial commercial and economic footprint, as summarised below.
| Metric | Figure |
|---|---|
| Global population with insomnia symptoms | 10–30% (up to ~237M affected) |
| Global sleep economy / sleep aids market by 2032 | US$950Bn |
| Australians with at least some insomnia symptoms | ~60% |
| Estimated cost to the Australian economy | A$19.1 billion |
| Projected Australian OTC CBD market | US$125M+ per annum |
In August 2023, the Australian Government issued a statement indicating that sleep health should be considered a national priority, as important as fitness and nutrition.
Why the regulatory pathway matters for investors
A successful Phase III trial is Avecho’s final clinical step in support of a submission to the TGA for pharmaceutical registration of the CBD TPM soft-gel capsule for the management of insomnia.
The opportunity is particularly significant in Australia, where regulatory changes in 2020 allow for over-the-counter sales of CBD products direct from pharmacy without a prescription, provided they gain appropriate approvals.
According to the company, Avecho has an opportunity to be the first in this area, as no other Phase III CBD trials in Australia have succeeded. Initial projections estimated the Australian over-the-counter CBD market would grow to over US$125M per annum.
What happens next
The company has outlined a clear pathway to completing enrolment:
-
Existing clinical sites have recommenced recruitment.
-
Additional sites will be progressively activated to support and accelerate enrolment.
-
Approximately 320 additional participants will be enrolled, with the final number confirmed as recruitment progresses and sufficient participants included to replace any who withdraw.
-
Recruitment of the remaining participants is expected to be completed within approximately 12 months once additional sites are operational.
Avecho intends to apply the recruitment strategies, site-management processes and operational improvements developed during the first stage of the study to complete enrolment efficiently.
For readers wanting to understand the recruitment process that produced the 244-participant interim dataset, our detailed coverage of how the interim cohort was recruited walks through the site activation steps, timeline, and what completion of that first stage meant for the programme ahead of the June 2026 analysis.
Dr Paul Gavin, Chief Executive Officer
“We are now applying the recruitment strategies, site-management processes and operational improvements developed during the first stage of the study to complete enrolment efficiently. Our existing sites have recommenced recruitment, and we will progressively bring additional sites online to accelerate enrolment as we drive this pivotal study through to completion.”
Efficacy and treatment allocation data will not be available until the study has been completed and the final data analysed. Investors should note that no interim efficacy readout is expected ahead of that final analysis.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.